Want to see IMNN full AI Analyst Report?
Top Page
Imunon
(NASDAQ:IMNN)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-0.66% Downside)
Action:Reiterated
Date:08/11/26
IMNN scores low primarily due to very weak financial performance (no meaningful revenue, persistent losses, and elevated recent cash burn/debt) and a bearish technical setup (price below key moving averages with negative MACD). The earnings call adds some offset from strong clinical/safety updates and better-than-planned enrollment, but near-term funding needs keep the overall score constrained.
Positive Factors
Phase II overall survival gains
Robust Phase II OS improvement is a durable clinical validation that materially de-risks the program versus competitors, strengthens regulatory and investigator confidence, and supports future partner interest and commercial potential if replicated in Phase III and final OS.
Negative Factors
No meaningful revenue; persistent losses
As a clinical-stage biotech, the company lacks recurring product revenue and posts large net losses. This structural lack of internal cash generation makes long-term program funding dependent on external capital, increasing dilution risk and limiting financial resilience over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase II overall survival gains
Robust Phase II OS improvement is a durable clinical validation that materially de-risks the program versus competitors, strengthens regulatory and investigator confidence, and supports future partner interest and commercial potential if replicated in Phase III and final OS.
Read all positive factors
Imunon (IMNN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.87M
Dividend YieldN/A
Average Volume (3M)180.69K
Price to Earnings (P/E)―
Beta (1Y)-0.78
Revenue GrowthN/A
EPS Growth71.67%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.53
Shares Outstanding5,611,403
10 Day Avg. Volume410,974
30 Day Avg. Volume180,689
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.50Price Target Upside1058.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.52
Revenue Forecast (FY)N/A
Imunon Business Overview & Revenue Model
Company Description
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifi...
How the Company Makes Money
Imunon primarily seeks to generate future revenue by advancing its internally developed product candidates through clinical development toward regulatory approval and, if approved, commercializing them directly and/or through partners; however, as...
Imunon Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and translational momentum (robust Phase II OS gains, encouraging MRD signals, favorable safety) and operational execution (enrollment outperforming assumptions, cost discipline, recent financing), balanced against near-term financing needs and uncertainties tied to small MRD sample size and event-driven timing of Phase III interims. Overall the positives (clinical validation, enrollment traction, operational control) outweigh the negatives (short runway, need for additional capital, statistical limitations of MRD).Positive Updates
Compelling Phase II Overall Survival Gains
OVATION II demonstrated a 14.7-month median overall survival (OS) improvement (45.1 months vs 30.4 months), a +48.4% relative increase. Among patients receiving PARP inhibitor maintenance, OS improved by 24.2 months (65.6 months vs 41.4 months), a +58.5% relative increase. Company plans to present final OS data in early 2027.
Negative Updates
Limited Near-Term Cash Runway and Need for Additional Capital
Management believes current cash, plus the June financing and cost discipline, supports operations through year-end 2026, but additional capital will be required to support full execution of the Phase III trial and other needs. The $10 million financing may be insufficient for full Phase III funding and the company is actively exploring options.
Read all updates
Q2-2026 Updates
Positive
Negative
Compelling Phase II Overall Survival Gains
OVATION II demonstrated a 14.7-month median overall survival (OS) improvement (45.1 months vs 30.4 months), a +48.4% relative increase. Among patients receiving PARP inhibitor maintenance, OS improved by 24.2 months (65.6 months vs 41.4 months), a +58.5% relative increase. Company plans to present final OS data in early 2027.
Read all positive updates
Company Guidance
The company’s guidance emphasized continued rapid execution across clinical, operational and financial fronts: OVATION III enrollment is outpacing plan at ~0.5 patients/site/month (vs plan 0.3 and historical ~0.2), with ~35% of planned sites active or activating and roughly 2x the needed sites identified; interims are event‑driven and will follow full enrollment. Clinical readouts and validation remain strong: OVATION II showed a +14.7‑month median OS benefit (45.1 vs 30.4 months) and a +24.2‑month benefit with PARP inhibitor maintenance (65.6 vs 41.4 months); MRD trial preliminary data favored IMUNON on MRD positivity (44% vs 67%), ctDNA clearance (87.5% vs 62%) and no‑evidence‑of‑disease rates (100% vs 56%); safety to date shows no CRS, no systemic toxicities and no serious immune‑related AEs and the IDMC identified no new safety concerns. Financially, Q2 R&D was $1.5M (vs $1.2M LY), G&A $1.3M (down ~20% vs $1.6M LY), net cash used in operations was $3.0M in Q2 (vs $4.0M in Q1), cash was $6.9M as of 6/30/2026, and the company completed up to $10M financing in June (no warrants), supporting runway through year‑end while additional capital is being sought; near‑term event milestones include R&D Day on Sept 23, SITC Nov 2026 and planned presentation of final OS data in early 2027.Imunon Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 500.00K |
| Gross Profit | -166.54K | 0.00 | 0.00 | 0.00 | 500.00K | 500.00K |
| EBITDA | -14.06M | -13.80M | -17.90M | -19.88M | -31.71M | -20.88M |
| Net Income | -14.72M | -14.49M | -18.62M | -19.51M | -35.90M | -20.77M |
Balance Sheet | ||||||
| Total Assets | 14.99M | 12.29M | 9.72M | 21.92M | 43.98M | 74.05M |
| Cash, Cash Equivalents and Short-Term Investments | 6.86M | 8.78M | 5.87M | 15.70M | 32.75M | 49.39M |
| Total Debt | 7.85M | 1.01M | 1.14M | 1.62M | 6.27M | 6.63M |
| Total Liabilities | 10.80M | 5.23M | 5.47M | 8.53M | 14.65M | 18.25M |
| Stockholders Equity | 4.19M | 7.06M | 4.24M | 13.39M | 29.33M | 55.80M |
Cash Flow | ||||||
| Free Cash Flow | -4.07B | -14.18M | -18.88M | -19.47M | -23.36M | -16.54M |
| Operating Cash Flow | -4.00B | -13.90M | -18.85M | -19.02M | -23.10M | -16.22M |
| Investing Cash Flow | -69.08M | -280.57K | 9.83M | 11.01M | 8.28M | -30.12M |
| Financing Cash Flow | 11.02B | 17.09M | 9.06M | -3.64M | 6.72M | 54.77M |
Imunon Technical Analysis
Negative
1.51
Price Trends
1.76
Negative
2.21
Negative
2.87
Negative
Market Momentum
-0.05
Negative
40.98
Neutral
30.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Negative. The current price of 1.51 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.76, and below the 200-day MA of 2.87, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.98 is Neutral, neither overbought nor oversold. The STOCH value of 30.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNN.
Imunon Risk Analysis
Imunon disclosed 4 risk factors in its most recent earnings report. Imunon reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Imunon Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $54.35M | -0.06 | 0.62% | ― | ― | 86.74% | |
48 Neutral | $13.36M | -0.90 | -77.34% | ― | ― | 59.81% | |
46 Neutral | $8.87M | -0.35 | -341.23% | ― | ― | 71.67% | |
45 Neutral | $160.78M | -1.85 | -116.86% | ― | -98.25% | 76.83% |
* Healthcare Sector Average
IMNN
Imunon
1.58
-4.99
-75.95%
KZIA
Kazia Therapeutics
13.67
6.37
87.26%
PHIO
Phio Pharmaceuticals
1.21
-0.86
-41.55%
GNPX
Genprex
3.95
-154.23
-97.50%
RNAZ
TransCode Therapeutics
2.97
-6.45
-68.47%
Imunon Corporate Events
Executive/Board Changes
Imunon Names Josh Blacher Interim Chief Financial Officer
Neutral
Jun 30, 2026
On June 29, 2026, Imunon announced that interim Chief Financial Officer Jeffrey Church, who has served in the role since January 2026, will retire effective July 1, 2026, with his departure attributed solely to retirement and no disagreements with...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Imunon Shareholders Expand Stock Incentive Plan, Back Governance
Positive
Jun 16, 2026
At its 2026 Annual Meeting of Stockholders held on June 16, 2026, Imunon shareholders approved an amendment to the company’s 2018 Stock Incentive Plan, adding 1,000,000 shares and raising the plan’s aggregate share limit to 1,265,004 s...
Business Operations and StrategyPrivate Placements and Financing
Imunon Secures $10 Million Non-Dilutive Structured Financing
Positive
Jun 4, 2026
On June 2, 2026, IMUNON entered into a securities purchase agreement with Streeterville Capital for a $10 million structured financing that closed on June 3, 2026, combining $2.5 million of non-convertible Series A preferred stock with $7.72 milli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.